Skip to main content

Home/ Health affairs/ Group items tagged penalties

Rss Feed Group items tagged

pharmacybiz

VAT penalties regime UK : New updation 2023 - 0 views

  •  
    The VAT penalties regime has had substantial changes with effect from 01 January 2023 and it is important for community pharmacy business owners to take note as this is a crucial cash inflow for most. Below we explore the changes that will impact all VAT registered community pharmacy businesses. Old regime Prior to 01 January 2023, VAT registered businesses that failed to file their VAT returns or pay any VAT liabilities would be subject to the default surcharge regime. There would be no surcharge for NIL or repayment VAT returns which would apply to most community pharmacy businesses. New regime For VAT periods starting on or after 01 January 2023, the default surcharge will be replaced by a new VAT penalties and interest regime if you submit your VAT returns late or pay your VAT liability late. If you pay your VAT monthly or quarterly, the deadline for filing your VAT return and paying any VAT liabilities is one calendar month and 7 days after the end of the respective period. For example, if you are filing the VAT return for the month or quarter ended 30 June 2022, the deadline for filing will be 07 August 2022. The liability must also be paid and cleared by that date.
P3 Healthcare Solutions

Avoid up to 9% Penalty for MIPS 2021 with P3Care - 1 views

  •  
    Avoid up to 9% penalty and earn up to 5% incentives with successful MIPS data submission. P3Care, being one of the leading MIPS Qualified Registries, is your partner to decode high points.
pharmacybiz

Advanz Pharma,PE Firms fined £84M Penalty : Price Inflation - 0 views

  •  
    Advanz Pharma, alongside London-based private equity firms Cinven and HgCapital, is collectively confronted with an £84 million penalty for inflating the price of the thyroid drug by over 1,000 per cent, soaring from £20 to £248 per package over an eight-year period. The Competition Appeal Tribunal endorsed 'all key aspects' of the Competition and Markets Authority's verdict on the companies' culpability in the case, the CMA has said. Advanz stood as the sole supplier of liothyronine tablets, essential for treating thyroid hormone deficiency, with the cost of a packet of these tablets surging over 12-fold between 2009 and 2017. Although Advanz Pharma currently possesses ownership of the company, its former owners, PE firms Cinven and HgCapital, also bear responsibility for the imposed fine, the CMA said. "NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016," Britain's competition watchdog said.
pharmacybiz

File Your Company Accounts on Time:Personal liability - 0 views

  •  
    All companies must send their accounts to Companies House each year. Recent evidence suggests that UK companies are increasingly struggling to file their accounts on time, with around 213,000 private companies reportedly missing their deadline in 2019-2020, resulting in over £93 million of penalties being issued. Over a fifth of companies that filed their accounts late that year had also filed late in the previous year. Under the Companies Act 2006 ("the Act"), the deadline for private companies to file their annual accounts is nine months from the end of the accounting reference period. There are slightly different rules for filing your first set of annual accounts and if these cover a period of more than 12 months, you must deliver them to Companies House within 21 months of the date of incorporation or 3 months from the accounting reference date, whichever is longer. Not filing your accounts at Companies House in a timely manner is also a criminal offence (under section 451 of the Act) and directors can be personally fined in the criminal courts. It is likely to come as a shock to most company directors who receive a summons to attend the Magistrates' Court in Cardiff for a criminal prosecution, particularly directors in larger pharmacy companies where directors are often detached from the preparation of accounts and senior financial staff and accountants are instructed to take care of such matters.
P3 Healthcare Solutions

COVID-19: HIPAA Security and Privacy Guidelines Relaxed for Providers - 0 views

  •  
    The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation. It doesn't stop there, but HIPAA penalties won't apply to covered healthcare providers for practicing telehealth medicine using third-party applications such as Skype or Facebook Messenger
  •  
    The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation.
pharmacybiz

Hydrocortisone Price Abuse: CMA Upholds £130M Fines - 0 views

  •  
    The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority's (CMA) findings against two pharmaceutical manufacturers who consistently overcharged hydrocortisone tablets for over a decade. Auden/Actavis UK's pricing for the critical medicine 'hydrocortisone' from 2008 to 2018 constituted an abuse of their dominant market position, leading to fines nearing £130 million, CMA said in a statement. "These companies increased the price of this crucial medicine by over 10,000 per cent, soaring from 70p to £72 within that period. These are the highest ever CMA penalties upheld by the Tribunal," the CMA said. In July 2021, the CMA imposed fines exceeding £265 million on hydrocortisone manufacturers Auden Mckenzie and Actavis UK, which acquired Auden's business in 2015 and subsequently became Accord-UK. The fines were imposed for abuse of dominance and collusion by both the parent companies and potential competitors. The recent verdict, announced on September 18, comes five weeks after the Tribunal supported the CMA's decision in a separate case regarding the pricing of medicines supplied to the NHS. In that prior case, fines amounted to £84 million.
P3 Healthcare Solutions

Why Should Medical Billing Services be Strictly HIPAA Compliant? - 0 views

  •  
    A professional medical billing service will always comply with HIPAA regulations. In case of any negligence in this sector, physicians and billing companies may come under the attack of penalties and a bad reputation.
P3 Healthcare Solutions

Last-Minute Hacks for Small Medical Practices to Report MIPS 2019 - 1 views

  •  
    Small Medical Practices! P3Care has been doing well as MIPS Qualified Registry for four years now. During this time, we come up with many little tricks to achieve a minimum performance threshold to be safe from the penalty. Read the article below to know how small practices can avoid the negative payment adjustment in MIPS 2019 reporting.
P3 Healthcare Solutions

Reimbursement Trends of 2020: MIPS Vs. Fee for Service - 1 views

  •  
    Clinicians concerning MIPS in 2020 face serious penalty consequences for not reporting MIPS 2020. They won't be able to get away with it if they don't participate resulting in a 9% deduction from their yearly Medicare payments.
pharmacybiz

UKVIA:Pharmacy sales of vape not solution curb underage use - 0 views

  •  
    Restricting sales of vape products to pharmacies is not a solution to curb illegal sales of vape among underage adults, said UK Vaping Industry Association (UKVIA). In an oral evidence at the House of Commons on 'Youth Vaping' called by the Health and Social Care Select Committee (HSSC) to figure out action needed to reduce vaping among those under 18. Rachael Maskell, York Central MP's suggested on vape products being available from licensed pharmacies. Marcus Saxton, Chairman, Independent British Vape Trade Association (IBVTA) said: "We are calling for further regulation to tighten up what has now been an extreme growth in single-use products. If you put them into those environments, as New Zealand and Australia are telling us, the perception of the public is that, while they can buy tobacco freely anywhere, the vaping product that is up to 95% safer is licensed through a pharmacy. It makes absolutely no sense. The negative consequence of considering such a thing will take us backwards years."
1 - 10 of 10
Showing 20 items per page